{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gottschlich A"],"funding":["European Research Council"],"pagination":["1536-1552"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12002222"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["145(14)"],"pubmed_abstract":["<h4>Abstract</h4>The success of targeted therapies for hematological malignancies has heralded their potential as both salvage treatment and early treatment lines, reducing the need for high-dose, intensive, and often toxic chemotherapeutic regimens. For young patients with classic Hodgkin lymphoma (cHL), immunotherapies provide the possibility to lessen long-term, treatment-related toxicities. However, suitable therapeutic targets are lacking. By integrating single-cell dissection of the tumor landscape and an in-depth, single-cell-based off-tumor antigen prediction, we identify CD86 as a promising therapeutic target in cHL. CD86 is highly expressed on Hodgkin and Reed-Sternberg cancer cells and cHL-specific tumor-associated macrophages. We reveal CD86-CTLA-4 as a key suppressive pathway "],"journal":["Blood"],"pubmed_title":["Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma."],"pmcid":["PMC12002222"],"funding_grant_id":["756017","101100460","101124203"],"pubmed_authors":["Hoffmann GV","Oner A","Endres S","Mesquita P","Brockelmann PJ","Gartig J","Simnica D","Tsiverioti CA","Baran-Marszak F","Briukhovetska D","Stock S","Grunmeier R","Hellmuth J","Igl V","Thomas M","Lorenzini T","Michaelides S","Schulz H","Mulkers M","Carlini E","Nandi S","Kaiser R","Trefny MP","Strzalkowski T","Nicolai L","Gelebart PF","Janert TA","Fairley SD","Di Fina L","Klapper W","Megens RTA","Frenz-Wiessner S","Marr C","Piseddu I","Reinke S","Kobold S","Muller PJ","von Bergwelt-Baildon M","Gottschlich A","Klein C","Kavaka V","Thelen M","Rosenwald A","Jobst J","Markl F","Beltran E","Brabenec R"],"additional_accession":[]},"is_claimable":false,"name":"Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.","description":"<h4>Abstract</h4>The success of targeted therapies for hematological malignancies has heralded their potential as both salvage treatment and early treatment lines, reducing the need for high-dose, intensive, and often toxic chemotherapeutic regimens. For young patients with classic Hodgkin lymphoma (cHL), immunotherapies provide the possibility to lessen long-term, treatment-related toxicities. However, suitable therapeutic targets are lacking. By integrating single-cell dissection of the tumor landscape and an in-depth, single-cell-based off-tumor antigen prediction, we identify CD86 as a promising therapeutic target in cHL. CD86 is highly expressed on Hodgkin and Reed-Sternberg cancer cells and cHL-specific tumor-associated macrophages. We reveal CD86-CTLA-4 as a key suppressive pathway ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-02T06:44:02.493Z","creation":"2026-04-15T03:14:51.793Z"},"accession":"S-EPMC12002222","cross_references":{"pubmed":["40178843"],"doi":["10.1182/blood.2023022197"]}}